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Abstract
Purpose: To present a novel design of an implantable glaucoma valve based on ferrofluidic nanoparticles and to compare it
with a well-established FDA approved valve.
Setting: Massachusetts Eye & Ear Infirmary, Boston, USA.
Methods: A glaucoma valve was designed using soft lithography techniques utilizing a water-immiscible magnetic fluid
(ferrofluid) as a pressure-sensitive barrier to aqueous flow. Two rare earth micro magnets were used to calibrate the opening
and closing pressure. In-vitro flow measurements were performed to characterize the valve and to compare it to AhmedTM
glaucoma valve. The reliability and predictability of the new valve was verified by pressure/flow measurements over a
period of three months and X-ray diffraction (XRD) analysis over a period of eight weeks. In vivo assessment was performed
in three rabbits.
Results: In the in vitro experiments, the opening and closing pressures of the valve were 10 and 7 mmHg, respectively. The
measured flow/pressure response was linearly proportional and reproducible over a period of three months (1.8 ml/min at
12 mmHg; 4.3 ml/min at 16 mmHg; 7.6 ml/min at 21 mmHg). X-ray diffraction analysis did not show oxidization of the
ferrofluid when exposed to water or air. Preliminary in vivo results suggest that the valve is biocompatible and can control
the intraocular pressure in rabbits.
Conclusions: The proposed valve utilizes ferrofluid as passive, tunable constriction element to provide highly predictable
opening and closing pressures while maintaining ocular tone. The ferrofluid maintained its magnetic properties in the
aqueous environment and provided linear flow to pressure response. Our in-vitro tests showed reliable and reproducible
results over a study period of three months. Preliminary in-vivo results were very promising and currently more thorough
investigation of this device is underway.
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Introduction
Glaucoma is a group of diseases that cause loss of vision due to
progressive degeneration of the retinal ganglion cells. [1,2] The
pathogenesis of the disease is still unknown, but it is well
established that lowering the IOP can slow down the progression
of the disease. [3,4] To date, IOP regulation is the primary target
in glaucoma management and is obtained either pharmaceutically
(topical or systemic pressure-lowering drugs) or surgically (trabec-
ular filtration surgery or drainage device implantation).
Among the various surgical procedures, drainage devices have
gained popularity mostly due to their ease of use, their efficacy in
IOP reduction and due to the growing concerns about late
complications associated with standard filtering surgery. [5,6].
Most glaucoma drainage devices are fitted with a soft silicone
tube end that is inserted in the anterior chamber (AC) through a
scleral fistula that shunts aqueous humor (AH) to an end plate with
flow resistance. In plated valves, the end plate is surgically placed
under the conjunctiva in the equatorial region of the globe.
Variations on plate size and valve/shunt architectures have been
described previously.[6–9] These variations were shown to affect
both the IOP as well as the overall function of these devices. The
main drawback in the current designs is that they rely on the
additional flow resistance provided by the conjunctival plate
encapsulation. [5,9] As a consequence, the majority of post-
operative complications are associated with the encapsulation
process resulting in early hypotony or later ocular hypertension.
[6,10] Other factors that may contribute to this process include
ocular injuries, inflammation and autoimmune syndromes. [9]
Other non-valved shunts, such as the ExpressTM are also placed
under a partial-thickness scleral flap which carries similar
complication rate of bleb encapsulation as the current valves. [11].
As a result, there is a clear need for a valve that can reliably and
predictably regulate the IOP without relying on the additional
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resistance from encapsulation (bleb). It will also be advantageous
to have a device designed for external placement of the outlet tip
(plate) while, most important, providing a good closing pressure
thus preventing hypotony. Such valve arrangement could poten-
tially address the complication of plate encapsulation, especially in
keratoprosthesis patients with cicatrizing ocular diseases. [9] The
possibility of placing the outlet tip at the lower lid fornix could
provide accessibility for observation and replacement under a slit-
lamp during a routine clinic encounter.
Ferrofluids are made of magnetic nanoparticles suspended in an
inert, non-magnetic carrier fluid. Due to their small size, typically
10 to 100 nm in diameter, the particles are subject to Brownian
motion. Small magnetite (Fe3O4) particles consist of a single
magnetic domain and exhibit super-paramagnetic properties, i.e. a
drag force along field gradients. To prevent aggregation, the
particles are coated with a surfactant that is compatible with the
carrier fluid they are suspended in. [12] Hence, in the presence of
a static magnetic field, the interfacial force will cause the ferrofluid
to conform to its boundaries. Thus, a ferrofluid in a capillary tube
can act as an on/off valve to flow through capillary blockade. In
order to generate an aqueous flow barrier, both the carrier fluid
and the surfactant must be non-polar to provide water immisci-
bility. Then, a permanent magnet can be used to hold the
ferrofluid in the capillary and a secondary magnet can be used to
adjust the force required to form the capillary barrier. When the
pressure exerted on the ferrofluid by the liquid exceeds the
magnetic force between the secondary magnet and the ferrofluid,
the barrier is broken and flow can initiate. Typically, the distance
between the secondary magnet and the ferrofluid determines the
strength of this barrier as will be described in more detail below.
Within this work, we present a novel, easily replaceable,
ferromagnetic valved tube capable of providing pressure regula-
tion without the necessity of subconjunctival encapsulation. We
describe the design architecture and characterize its performance
in an in-vitro manometric setup. In addition we compare the
performance of the new ferrovalve with an FDA approved
glaucoma valve (AhmedTM). Finally, we undertake characteriza-
tion of the ferrofluid under long-term water and air exposure using
X-Ray diffraction (XRD) analysis.
Methods
Design of the Ferrovalve
The design of the valve was based on soft lithography
techniques using polydimethylsiloxane (PDMS), a very well
characterized and biocompatible polymer. Sylgard 184 (Dow
Corning Corporation, Midland, MI, USA) flexible silicon elasto-
mer was used with a base to curing agent ratio of 10:1 by weight,
to prepare the liquid pre-polymer.
The design of the valve involved 4 steps:
In step 1, a master mold was created using permanent epoxy
negative photoresist SU-8 3050 (MicroChem corporation, New-
ton, MA, USA). The SU-8 was spin-coated on a 3 inches silicon
wafer and exposed to UV light using a photo mask with the desire
features (1000 rpm/100 mm feature size). After developing the
master, PDMS was poured over the master and cured by baking at
65uC overnight (Figure 1).
In step 2, a capillary tube of clear fused quartz (VitroCom
Mountain Lakes, NJ, USA) with inner diameter (ID) 300
micrometers and outer diameter (OD) 400 micrometers was
silanized by flushing it with a PEG-silane solution ([methoxy(po-
lyethyleneoxy)propyl]trichlorosilane, Gelest SIM6492.66). The
capillary was then cut to 5.5 mm length using a diamond blade
and inserted into a soft silicone tube of 300 micrometers ID (VWR
International 60985–700 0.30 mm ID and 0.61 mm OD). The
tube was then mounted on the PDMS mold (from step 1) with two
1/160 cubic rare earth magnets (Nd2Fe14B, K&J Magnetics, Inc.,
Jamison, PA, USA). The PDMS was placed on a silicon wafer in a
petri dish and PDMS pre-polymer was poured and cured at 65u C
over night to embed the capillary tube and magnets in PDMS.
In step 3, the device was cut out from the bulk PDMS (step 2)
and trimmed to its desired shape and size (2.864.762.7 mm in
Length x Width x Height). One millimeter length of silicon tube
was left on both sides for tube connection. A stainless steel tube of
400 micrometer OD and 12 mm length (New England Small
Tube, Litchfield, NH, USA) was used to interconnect the valve
with a longer soft silicone tube (VWR International 60985–700).
The connection was secured with PDMS.
In step 4, a small amount of ferrofluid (,0.1 mL), generously
provided by Ferrotec corporation (Bedford, NH, USA), was
introduced into the capillary using a 30 gauge needle. The
ferrofluid was made of 10 nm monodispersed Fe3O4 particles
suspended in a fluorocarbon carrier oil. The ferrofluid has a
viscosity of 367 cP and maximum magnetization of 404 Gauss (NF
3914). The ferrofluid was securely fixed by the magnetic force of
the two micro magnets, such that the primary micro magnet next
to the tube holds the ferrofluid in place while the secondary acts as
a pressure regulator (Figure 2).
Calibration and Characterization of the Ferrovalve
Before building the final prototype of the ferrovalve with all
components embedded in PDMS, we set up a modular system in
which the magnets could be moved in respect to the capillary tube
containing the ferrofluid, in order to study the pressure/flow
characteristics of the design. The setup was as follows:
The capillary valve was placed on a micro stage (Thorlabs,
Newton, NJ, USA) and connected to a reservoir containing
distilled water (dH2O) via a 40 cm silicone tube (VWR Interna-
tional 60985–700 0.30 mm ID and 0.61 mm OD). The primary
micro magnet was placed adjacent to the capillary valve with the
north magnetic pole towards the direction of the ferrofluid. A
second micro magnet was placed on a separate micro stage with its
south magnetic pole facing the primary magnet (Figure 3).
The primary magnet served as a fixation of the droplet by
providing the highest magnetic attraction on the ferrofluid, while
the secondary magnet placed at the opposite distal end served to
control the opening and closing pressures of the valve. In this way,
the configuration of the PDMS device is replicated in a discrete
fashion that allows adjusting the distance between the second
magnet and the ferrofluid inside the capillary tube.
Each magnet had a surface field of 5754 Gauss providing a
pulling force of 68 g. The maximum energy product ((BH)max) of
each magnet was about 42 MGauss?Oersted (according to the
specifications of the manufacturer).
For experiments aiming at physiologically relevant pressures,
the distance of the secondary magnet was adjusted to provide flow
opening at 10 mmHg of pressure.
A small amount of ferrofluid (0.1 mL) was introduced in the
capillary using a custom-made glass needle. Both magnets
provided bidirectional magnetic attraction to the ferrofluid with
the secondary having less magnetic effect than the primary due to
its greater distance from the capillary (figure 4). Hence, the
magnetic field lines going from one magnet to the other keep the
ferrofluid in place against the flow through the capillary. Only a
high-enough pressure provides the necessary force to displace the
ferrofluid sufficiently to form a channel and allow liquid flow
through the capillary.
Glaucoma Valved Tube
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The dH2O reservoir was elevated to a defined height to
generate a hydrostatic pressure difference, as calculated using the
following formula:
P = rgh.
[P: pressure, r: density of liquid, g = 9.8 N/kg and the value
equals gravitational acceleration, h: height of liquid in meters.].
The hydrostatic pressure was converted to millimeters of
mercury pressure by substituting the liquid density of water
(1.00 g/mL) by the density of Hg (13.55 g/mL). Pressure and flow
measurements were carried out continuously for 3 months.
Pressure calibration was achieved by adjusting the distance of
the secondary micro-magnet to obtain an opening and closing
pressure of 10 and 7 mmHg, respectively. The secondary micro-
magnet was offset horizontally to compensate for the ferrofluid
bending towards the flow direction. Various test pressures were set
by adjusting the height of the dH2O reservoir.
Characterization of the Ferrofluid
To study potential oxidation of the Fe3O4 nanoparticles to
Fe2O3, the ferrofluid was characterized using X-Ray diffraction
(XRD) crystallography. Samples of the ferrofluid were exposed to
either water or air for 8 weeks and chemical analysis was obtained
in order to evaluate the oxidization on the nanoparticles. The
nanoparticles in the ferrofluid were investigated by large angle X-
ray diffraction (XRD, Scintag XDS2000). The peaks of 2h
obtained by the X-ray diffractogram were correlated using the
International Center for Diffraction Data and crystal structure and
composition was identified. In addition, the ferrofluid was assessed
under an optical microscope over the course of the experiment in
order to evaluate its integrity.
The interaction between the ferrofluid and the glass capillary
was assessed with contact angle and adhesion measurements. A
computer-controlled CCD camera (Sony XCD-V50) with green
LED background illumination was used to measure the contact
angle of a ferrofluid droplet on hydrophilic and hydrophobic
coated glass slide in order to assess the surface interaction between
the glass and the ferrofluid. The glass slides we silanized with
either a perfluorosilane (hydrophobic) or PEG-silane (hydrophilic),
while one slide was left non-coated. All slides were thoroughly
cleaned by rinsing them several times with ethanol and water, and
blown dry with compressed filtered air. Contact angle measure-
ments were obtained in air and water interface using a custom-
Figure 1. A silicon wafer with 100 mm height features of negative SU-8 photoresist. The design was used as a master mold for the valve.D.
doi:10.1371/journal.pone.0067404.g001
Figure 2. A prototype implantable ferromagnetic glaucoma valve (ferrovalve). Size comparison with one US cent coin (left), the tip of a
pen (center) and a ruler of 1 cm scale (right). The size of the valve is 2.864.762.7 mm in Length x Width x Height. You can also distinguish the circular
PDMS peg on the tube for scleral suturing.
doi:10.1371/journal.pone.0067404.g002
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made glass cuvette (figure 5). The adhesion of the ferrofluid to the
various substrates was probed using a jet of pressurized air in an
attempt to blow away the ferrofluid droplet from the substrate.
The results were optically captured as remaining deposits of
ferrofluid on substrates. This qualitative assessment provided
insights to the surface interaction between the different coatings
and the ferrofluid.
Further evaluation of the glass coatings was undertaken with
contact angle measurements of water and Fluorinert FC77 oil
droplets in air and immersed under water.
AhmedTM valve
In order to compare the pressure and flow measurements of the
ferrovalve with the current standard of care, we used the
commercially available, well established, and FDA-approved
AhmedTM Glaucoma Valve (New World Medical Inc., Rancho
Cucamonga, CA). The AhmedTM PF-7 silicone valve was
connected to the same dH2O reservoir, as previously described.
Flow vs. pressure measurements were recorded and the opening
and closing pressure was determined in similar fashion as for the
ferrovalve.
In vivo Experiments
The use of animals for this study was approved by the Animal
Care Committee of the Massachusetts Eye and Ear Infirmary, and
all animal procedures were performed in accordance with the
ARVO Statement for the use of Animals in Ophthalmic and
Vision Research and the National Institute of Health Guidance for
the Care and Use of Laboratory Animals.
Implantation was performed in three NZ White/NZ Red
crossed rabbits (male, weighing 4.3–4.5 Kg). The ferrovalve
housing was connected with a 35 mm of silicone tubing (inner
diameter = 300 mm; outer diameter = 610 mm) that was trimmed
during the surgery and placed at the lower lid fornix temporally.
The tubing was then inserted beneath the conjunctiva and was led
up to the supra-temporal limbus. The tip was then inserted into
the posterior chamber of the eye using a 25 G needle. A small peg,
previously attached to the tubing, was anchored to the sclera with
two 10-0 Nylon sutures, for stability. Thus, the tubing extended
subconjunctivally to enter the eye from a point in the lower fornix.
The ferrovalve housing remained exterior to the conjunctiva at the
inferior lid fornix (Figure 6).
The animals were treated daily with topical Polytrim (polymyx-
in B/trimethoprim, Allergan, Inc., USA) and Pred-forte (prednis-
olone acetate 1%, Allergan, Inc., USA), and followed for two
weeks. Eyes were assessed for inflammation and infection and
daily IOP measurements were performed.
Results
Pressure Calibration
A water-immiscible ferrofluid droplet of 0.1 mL volume was
placed in the tube. The primary magnet was placed in contact
with the tube subsection containing the ferromagnetic droplet and
both were mounted on a microstage (mStage 1). A second magnet
was placed on a different microstage (mStage 2), moving vertically
and opposite to the first (mStage 1). By adjusting the horizontal
spacing between the mStage 1 and mStage 2 to 500 mm, the
magnetic field of the secondary magnet on the ferrofluid droplet
was weakened, thus obtaining an opening and closing pressure of
10 and 7 mmHg, respectively. This pressure calibration was
maintained over the entire duration of the experiment (3 months)
with small variations that resulted to pressure drift of less than
0.5 mmHg. Experimental results at pressure of 7 mmHg over a
period of one week showed no flow or significant leak. Similarly,
Figure 3. Valve calibration using twomovable micro stages. The first stage contains the tube with a micro magnet providing strong magnetic
field on the ferrofluid. The second contains a micro magnet which position can be adjusted to provide weaker magnetic field on the ferrofluid.
doi:10.1371/journal.pone.0067404.g003
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over a period of 30 days the pressure was varied between 7, 12, 16,
and 21 mmHg. The resulting opening and closing pressure was
maintained as initially calibrated (open: 10 mmHg/close:
7 mmHg) with a small variability of 60.5 mmHg. The flow/
pressure response of the valve showed increase of flow at higher
pressures (1.8 ml/min at 12 mmHg; 4.3 ml/min at 16 mmHg;
7.6 ml/min at 21 mmHg). Flow variations were clinically insignif-
icant during the study period (60.2 mL/min at 12 mmHg).
Analyzing the data collected during the 3 months of experimen-
tation, a linear response was found between flow and pressure
(Adjusted R2= 0.971) (figure 7). The results represent the mean
flow rate at 7, 12, 16 and 21 mmHg of pressure over a period of
three months under varying pressure conditions.
At 12.5 mmHg of pressure the outflow facility achieved was
equal to the aqueous humor (AH) production rate in normal eyes
(,2.5 mL/min). These results suggest that as long as the valve
functions under the pre-defined specifications, the pressure in the
eye cannot exceed the upper threshold of 12.5 mmHg, even if the
valve filters the total AH volume produced per minute.
However, presuming some remaining functionality of the
trabecular meshwork and the uveo-scleral pathway, which are
the principal AH draining sites in the normal eye, this pressure
could easily be reduced to 10 mmHg. Even at this pressure, the
valve would be able to drain approximately 50% of the AH
produced per minute. [13].
The mechanism of opening and closing is presented in figure 8,
which illustrates the shape change in the water immiscible
meniscus of ferrofluid under the influence of various pressures.
XRD Results
The ability of the magnetic Fe3O4 nanoparticles to withstand
oxidization was assessed over an 8 weeks period of exposure to
water and air. This experiment serves as a qualitative predictor of
the performance, integrity and durability of the ferrovalve.
X-ray diffraction (XRD) experiments were performed to
characterize the stability of the Fe3O4 particles suspended in a
fluorocarbon-based carrier fluid. The ferrofluid was exposed to
water and oxygen at room temperature. XRD results before
Figure 4. Representation of the ferrofluidic valve architecture. (a) Enlarged photograph of the valve. An adjustable micro magnet (left), the
capillary with the ferrofluid (center), and the fixed micro magnet (right). (b)Schematic diagram of the ferromagnetic valve.
doi:10.1371/journal.pone.0067404.g004
Glaucoma Valved Tube
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exposure, figure 9(a), and at 8 weeks post-exposure, figure 9(b),
showed that the 2h peaks (the peaks at approximately 30u and
35.5u) are characteristic of magnetite (Fe3O4), suggesting that the
ferrofluid remained chemically stable. Similar results were
previously obtained by the authors in additional experiments
testing the oxidization of the ferrofluid following three months of
flow/pressure exposure (data not shown).
The contact angle of the ferrofluid in air was wair< 25u for plain
glass; 13u for PEG-silane coated glass and 19u for fluorosilane
coated glass. However, the angle measurements in water interface
showed variable results between the coatings with the highest
angle achieved by the plain glass (wwater< 52u), and PEG (wwater<
48u) and the lowest with the fluorosilane coating (wwater< 32u),
figure 10 (a,b).
The contact angle of water was wair< 20u for the non-coated
glass, wair< 37u for the PEG-silane coated glass and wair< 104u for
the fluorosilane coated glass suggesting that the non-coated glass is
more hydrophilic than the PEG-silane coated glass, figure 11.
Figure 5. A computer-controlled CCD camera with green LED background illumination and a water cuvette for measuring the
contact angle of the ferrofluid droplet on coated and non-coated glass slide.
doi:10.1371/journal.pone.0067404.g005
Figure 6. Implantation of the ferromagnetic valve in a rabbit eye. Black arrow indicates the sub-conjunctival tunnel over the valve tubing. A)
The housing remains exterior at the bottom of the lower lid fornix. B) Flow of aqueous humor is shown in vivo.
doi:10.1371/journal.pone.0067404.g006
Glaucoma Valved Tube
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In a different experiment using Fluorinert (FC-77) oil,
simulating the carrier fluid of the ferrofluid, the contact angle in
air was wair< 5u for the non-coated glass, wair< 9u for the PEG-
coated and wair< 26u for the fluorosilane coated glass, while in
water was wwater< 143u for the non-coated glass, wwater< 124u for
the PEG-silane coated and wwater< 38u for the fluorosilane coated
glass.
Increase in hydrophilicity led to increase in contact angle
measurements. However, plain glass exhibited higher contact
angle measurements in water compared to the PEG coated glass.
The adhesion assessment of the ferrofluid with the glass was
achieved using a jet of pressurized air to blow away the ferrofluid
droplet from the glass surface. This has led to the qualitative
characterization of the interaction between the ferrofluid with the
Figure 7. Linearity of the pressure/flow relationship of the ferromagnetic valve (Adj. R2=0.971). The valve provides a flow rate of 1 mL/
min at 10 mmHg of pressure.
doi:10.1371/journal.pone.0067404.g007
Figure 8. The valve mechanism at different pressures. Closed at 7 mmHg (left), open at 13 mmHg (center), open at 18 mmHg providing
increased flow rate (right).
doi:10.1371/journal.pone.0067404.g008
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PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e67404
glass surfaces. The fluorosilane-coated glass exhibited the highest
adhesive interaction, followed by the PEG and with the plain glass
showing the least interaction, figure 9 (a–c).
AhmedTM Valve
In a series of repeated pressure/flow measurements with the
Ahmed valve, no closing pressure was recordable in an in-vitro set-
up with the outlet tip exposed to atmospheric pressure. Flow was
interrupted only when the dH2O container was completely empty.
Observation under the microscope revealed a continuous sheath
flow between the two parallel membranes that form the valve
mechanism. We also observed that when the accumulated water at
the outlet tip of the Ahmed valve was drained using a filter paper,
the water film between the membranes dewetted, which caused
the membranes to come into contact and interrupt the flow. The
closing pressure at that point was measured to be 2.5 mmHg with
a variation of +/22 mmHg.
In vivo Experiments
Implantation of the valve was successfully performed without
any complications in all three cases. The mean time of surgery was
approximately 40 minutes. The circular PDMS peg resulted in a
Figure 9. Stability analysis of magnetite Fe3O4 nano-particles exposed to water and air exposure using X-ray diffraction analysis.
(a) Top figure: X-ray diffraction analysis (XRD) of the ferrofluid pre-exposure to water and air. The 2h peaks at 30u and 35.5u are characteristic of
magnetite Fe3O4. (b) Bottom figure: X-ray diffraction analysis (XRD) of the ferrofluid post-exposure to water and air for 8 weeks. The 2h peaks at 30u
and 35.5u are characteristic of magnetite Fe3O4. No oxidization was observed on the ferromagnetic nano-particles.
doi:10.1371/journal.pone.0067404.g009
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good fixation of the tube to the sclera. During the 2 weeks of
follow-up, there were no signs of infection or inflammation other
than a brief period of irritation right after surgery. The
measurement of IOP was performed daily in both eyes, with the
mean values in the valve-implanted eye (11.862 mmHg), signif-
icantly lower than the contralateral control eye (1463 mmHg),
Figure 10. Contact angle measurements of the ferrofluid on different substrates in air (left) and water (center). Images on the right
show the different substrates after the drop of ferrofluid has been blown off with compressed air. (a) Plain glass (non-coated) contact angle and
adhesion measurements. (b) PEG-silane (hydrophilic) contact angle and adhesion measurements. (c) Fluorosilane (hydrophobic coating) contact
angle and adhesion measurements.
doi:10.1371/journal.pone.0067404.g010
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(P,0.0001; paired sample t-test). These values were in agreement
(+/22 mmHg) with those obtained in vitro.
At the last follow-up, two weeks after surgery, a continuous flow
was still noticed at the outlet tip of the valve, demonstrating
functionality during the time of post implantation observation.
Discussion
As previously described, pressure below 5 mmHg (‘‘hypotony’’)
may lead to many ocular complications and may result in loss of
vision as well as loss of the eye. [14] It is essential that any
implantable valve should maintain a critical closing pressure to
avoid hypotony. Available AH drainage devices, such as the
AhmedTM Glaucoma Valve and the BaerveldtH glaucoma implant
rely to various degrees on the extra resistance provided by the
subconjunctival encapsulation of the valve plate in order to
prevent hypotony. However, this encapsulation process is often
delayed and unpredictable due to variable degree of fibrosis of the
bleb. As a result, the post operative management is often
complicated by early hypotony that can cause influx of blood
into the anterior chamber, retinal bleeding and detachment and
later ocular hypertension that can accelerate the glaucoma
progression. Even though the AhmedTM valve is not usually
associated with early post-operative hypotony, our in-vitro results
suggest that it requires subconjunctival implantation to achieve a
closing pressure. No closing pressure was measured when the
outlet tip was exposed to atmospheric pressure. The water
between the valve membranes provide a continuous sheath flow.
We attributed the lack of closing pressure to water surface tension
preventing the membranes from complete de-wetting. During our
experiments we noticed that when the accumulated water at the
outlet tip of the valve was manually removed, a closing pressure
was achieved. We believe that the dewetting of the water film
between the two membranes caused the membranes to adhere.
However, under normal operating conditions of continuous flow
there was no closing pressure, suggesting that the AhmedTM valve
should not be used extraocularly.
Efforts have been made to shunt AH to atmospheric pressure
via a modified AhmedTM valve with a distal tube to the maxillary
sinus or to the lower lid fornix. [9] The incidence of endophthal-
mitis was extremely low and equal to standard trabeculectomy
(0.7% on the basis of 145 cumulative shunt years). In fact, the only
endophthalmitis encountered among 34 patients implanted with
such external valve shunt occurred after a tooth root abscess and
without signs of infection around the shunt. [9] However,
maintaining a closing pressure was impossible, rendering the eye
susceptible to hypotony and its associated visual consequences. In
contrast, the ferromagnetic valve, as described in this study, could
be placed externally in the lower lid fornix via a tube and provide
the desired closing pressure as well as an opening pressure. The
unidirectional flow of AH reduces the possibility of endophthal-
mitis even when the valve is extra ocular.
In this manuscript we present and characterize a novel
glaucoma valve based on ferromagnetic nanoparticles. In the
design of this valve we adhered to the general principles of
simplicity and efficacy. Our work demonstrates in-vitro reproduc-
ible closing and opening pressures of the valve with a hysteresis of
only 3 mmHg between opening and closing pressure.
The excellent pressure response was attributed to the ferrofluid’s
ability of the ferrofluid to radically alter its geometrical charac-
teristics at the event of pressure stimuli.
This work was undertaken in an attempt to address the
limitations of the commercially available devices, which rely on
encapsulation of the valve’s outlet to limit flow. Our promising
preliminary data suggest that further in-vivo evaluation should be
undertaken.
Ferromagnetic Calibration
A custom-made ferrofluid, consisting of water-immiscible
ferromagnetic nanoparticles that are dispersed in a fluorinated
oil as carrier liquid, was used for the design of the valve. Two
permanent NdFeB rare-earth micro magnets were used to provide
non-conduct adjustment of the ferrofluid droplet. The primary
magnet was placed next to the tube sub-section containing the
ferrofluid to hold the droplet from moving with the flow, while the
secondary magnet was placed opposite to the primary, adjusting
the pressure required to bend the droplet and initiate flow. The
bending force was evaluated using liquid flow at various pressures.
The ferromagnetic valve provided flow occlusion at a pressure of
7 mmHg and flow initiation at a pressure of 10 mmHg.
These results suggest that external implantation of the outlet tip
of the valve, such as at the lower lid fornix is possible without the
need of encapsulation for additional flow resistance. External
placement of the valve has the advantage of device accessibility for
direct observation and replacement when needed.
Ferrofluid Biocompatibility
Medical devices and their component materials may leak
compounds or have surface characteristics that can produce
undesirable effects when used clinically. However, based on the
FDA, ISO and JMHLW guidelines, the general testing framework
in the assessment of a device biocompatibility is different between
implantable and external communicating devices. Nevertheless,
any implantable device must comply with the safety and
biocompatibility regulations. The scope of this work was the in-
vitro evaluation of the device, thus literature research was
undertaken to assess the biocompatibility and safety of the
materials used.
Magnetic nanoparticles, such as Fe3O4, have been extensively
used in magnetic field induced localized hyperthermia for the
treatment of cancer,[15–17] for high contrast magnetic resonance
Imaging (MRI) and for iron deficiency due to hemodialysis.
[18,19] No adverse cytotoxic effects have been reported in intra-
venous (IV) administration. Similar nanoparticles were used in this
study.
Perfluoroalkylpolyether (PFPE) is used as carrier fluid and
surfactant to disperse the Fe3O4 magnetic nanoparticles. In
laboratory animal tests, as reported in the manufacturer’s
catalogue, the carrier liquid was found to have a low order of
actuate oral activity. The LD50 dose in rats was greater than
25,000 mg per kg of body weight (data provided by the
manufacturer).
There is no known hazard from short term skin exposure or
inhalation at room temperature, as true for other fluorocarbon oils
that are used in biomedical applications, such as during retinal
detachment surgery. [20,21].
Our new valve is designed such that the outlet tip will be placed
externally in the lower lid fornix. This will minimize the potential
ocular contents exposure to ferrofluid by the extra protection
afforded by the conjunctiva and tear film. In addition, the total
ferrofluid volume in the valve is approximately 0.1 mL, which is a
minute volume compared to the volume used in retinal
detachment surgeries (average 5 mL). We, therefore, expect good
biocompatibility of the device and steps towards in-vivo assessment
of the valve have already been taken by the authors.
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Flow Measurements
The flow capacity of this valve was studied in this paper under
different pressure regimes. The flow capacity of the valve was
considered as the second most important parameter in the in-vitro
evaluation. IOP is a function of the outflow capacity versus the AH
production rate at a given pressure. At a given IOP the valve
should be able to facilitate the volume of AH that is produced in
the eye per unit time.
Contact Angle Measurements
The variability in the water contact angle measurements was
attributed to the wettability of the glass slide. When the slides were
submerged into water, water molecules compete with the
fluorocarbon molecules in the wettability of the glass. As glass is
hydrophilic, water can wet the surface well and thus reduce the
contact area of the ferrofluid which results in a more compact
droplet. However, the resulting contact angle on the PEG-silane
coated slide was smaller than the plain glass, which led to the
assessment of the ferrofluid interaction with the coating. The
adhesion measurements of the ferrofluid on the glass slides showed
less interaction between the ferrofluid and the plain glass slide.
The results were confirmed using water and FC77 droplets on
non-coated and PEG-silane coated glass. Despite of the increased
hydrophilicity of the PEG-silane, non-coated glass hydrophilicity
was better, providing less adhesion of the ferrofluid on the glass.
These results suggest the non-coated glass is likely to perform
better due to the lower interaction with the ferrofluid.
Reducing the interaction of the ferrofluid with the capillary
walls was shown to provide better ferrofluid adhesion under high
flow rates, smoother bending of the ferrofluid under pressure and
less break-up in the event of micro air bubbles flowing through the
capillary which can cause gradual loss of the ferrofluid material.
XRD Results
Oxidization of ferromagnetic particles is a topotactical reaction
where magnetite (Fe3O4) can become maghemite (c-Fe2O3) upon
further oxidation. Such transformation could decrease the
saturation magnetization of the ferromagnetic particles, changing
the magnetic characteristics of the ferrofluid and permanently
affecting its reliability of the valve. [17].
In vivo Experiments
Implantation of the ferrovalve in 3 rabbit eyes showed
predictable IOP regulation for at least 2 weeks. No inflammation,
keratitis, or other adverse events were noted, indicating that the
valve was well tolerated and biocompatible. In a similar
arrangement in 34 patients operated between 2001–2005, [9] no
discomfort was noted by placing a modified AhmedTM valve at the
lower lid fornix. However, the study was stopped due to hypotony.
The limited discomfort of such an arrangement is attributed to the
lack of lower lid movement during blinking. The implantation of
the ferrovalve was technically uncomplicated. The use of non-
magnetic instruments is recommended to this surgery. The
circular PDMS peg used around the tube provided good fixation
to the sclera with additional sealing of the scleral tunnel. These
preliminary in vivo results were encouraging, and a larger in vivo
study with longer follow up is underway.
Study Limitations
One of the limitations of this device is the incompatibility with
static magnetic field produced either by permanent magnet of by
flow of direct current (DC), such as in magnetic resonant imaging
(MRI) systems. However, this is well known issue with other
implantable devices, such as pacemakers, implantable neurostim-
ulators, cochlear implants and osteosynthesis which face similar
limitations. In the scenario were MRI is inevitable, the valve can
be temporarily removed using a tight suture or a plug around the
tube to prevent AH leakage. More options will be evaluated in
future studies. Walk-through metal detectors, such as those used in
airports do not generate static magnetic fields since they operate in
alternate current (AC). However, Eddy currents can be generated
but are insignificant for the valve since it does not contain active
electronic elements. A broader clinical study incorporating more
animals is necessary to address the aforementioned limitations.
Nevertheless, preliminary in vivo results encourage further explo-
ration in this direction.
Conclusion
In this paper we describe the design and characteristics of a
novel glaucoma valve. The proposed device utilizes a ferrofluid to
provide highly predictable opening and closing pressures while
maintaining ocular tone. Moreover, our valve is suitable for
external implantation, which would facilitate maintenance and
replacement in a non-invasive fashion. Preliminary in vivo results
using rabbits suggest good tolerability and regulation of the IOP.
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